Abstract
Background: A subset of asthmatics shows refractoriness to Salbutamol owing to ADRB2 gene CT polymorphism (rs 1800888) that substitutes Thr to Ile at the position 164 in the β2 adrenergic receptor leading to sub-optimal binding of Salbutamol. The present study aims to associate the Salbutamol (200 mcg) refractoriness with the polymorphism and select the best existing agonist with optimal binding affinity against wild and mutated receptor and further identify high affinity compound, irrespectively targeting wild and mutated receptor through virtual screening methods. Methods: Responders to Salbutamol were categorized, if percentage reversibility was greater than or equal to 12% in them, while those showing reversibility less than 12% were non-responders. The genotyping for polymorphism was performed by ARMS PCR method. Established agonists with consistent binding affinity against wild and mutated receptors formed query compound to identify high affinity molecule from Phase database through 7 point pharmacophore based screening. Results: Polymorphism was significantly associated with non-responders (p= < 0.05) demonstrating it as a major factor of Salbutamol refractoriness. Results from Glide Docking showed that Fenoterol had highest affinity for mutated receptor and stood as second best (after Salbutamol) high affinity agonist for wild receptor among the established β2 agonists. Therefore Fenoterol formed a query molecule (7 point pharmacophore) in identification of high affinity compound for virtual screening process. Conclusion: Compound CACPD2011a-0001278239 identified through virtual screening against 4 million compounds in phase database was shown to irrespectively target both wild and mutated β2 adrenergic receptor with high and consistent affinity which was par greater than established β2agonists.
Keywords: ADRB2 polymorphism, β2AR receptor mutation, salbutamol, fenoterol, 7 point pharmacophore modeling, virtual screening.
Current Pharmaceutical Design
Title:Identification of Small Molecule as a High Affinity β2 Agonist Promiscuously Targeting Wild and Mutated (Thr164Ile) β 2 Adrenergic Receptor in the Treatment of Bronchial Asthma
Volume: 22 Issue: 34
Author(s): Srinivas Bandaru, Mallika Alvala, Jyothy Akka, Someshwar Rao Sagurthi, Anuraj Nayarisseri, Sanjeev Kumar Singh and Hema Prasad Mundluru
Affiliation:
Keywords: ADRB2 polymorphism, β2AR receptor mutation, salbutamol, fenoterol, 7 point pharmacophore modeling, virtual screening.
Abstract: Background: A subset of asthmatics shows refractoriness to Salbutamol owing to ADRB2 gene CT polymorphism (rs 1800888) that substitutes Thr to Ile at the position 164 in the β2 adrenergic receptor leading to sub-optimal binding of Salbutamol. The present study aims to associate the Salbutamol (200 mcg) refractoriness with the polymorphism and select the best existing agonist with optimal binding affinity against wild and mutated receptor and further identify high affinity compound, irrespectively targeting wild and mutated receptor through virtual screening methods. Methods: Responders to Salbutamol were categorized, if percentage reversibility was greater than or equal to 12% in them, while those showing reversibility less than 12% were non-responders. The genotyping for polymorphism was performed by ARMS PCR method. Established agonists with consistent binding affinity against wild and mutated receptors formed query compound to identify high affinity molecule from Phase database through 7 point pharmacophore based screening. Results: Polymorphism was significantly associated with non-responders (p= < 0.05) demonstrating it as a major factor of Salbutamol refractoriness. Results from Glide Docking showed that Fenoterol had highest affinity for mutated receptor and stood as second best (after Salbutamol) high affinity agonist for wild receptor among the established β2 agonists. Therefore Fenoterol formed a query molecule (7 point pharmacophore) in identification of high affinity compound for virtual screening process. Conclusion: Compound CACPD2011a-0001278239 identified through virtual screening against 4 million compounds in phase database was shown to irrespectively target both wild and mutated β2 adrenergic receptor with high and consistent affinity which was par greater than established β2agonists.
Export Options
About this article
Cite this article as:
Bandaru Srinivas, Alvala Mallika, Akka Jyothy, Sagurthi Rao Someshwar, Nayarisseri Anuraj, Singh Kumar Sanjeev and Mundluru Prasad Hema, Identification of Small Molecule as a High Affinity β2 Agonist Promiscuously Targeting Wild and Mutated (Thr164Ile) β 2 Adrenergic Receptor in the Treatment of Bronchial Asthma, Current Pharmaceutical Design 2016; 22 (34) . https://dx.doi.org/10.2174/1381612822666160513145721
DOI https://dx.doi.org/10.2174/1381612822666160513145721 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Volatile Oil of <i>Magnolia biondii</i> Pamp. for Transnasal Administration: Its
Preparation, Characterization, and Mechanism of Action in the
Treatment of Allergic Rhinitis
Current Drug Delivery The Effects of Lycopene and Tomato Consumption on Cardiovascular Risk Factors in Adults: A Grade Assessment Systematic Review and Meta-analysis
Current Pharmaceutical Design The Future of Post-Genomic Biology at the Proteomic Level: An Outlook
Combinatorial Chemistry & High Throughput Screening Blood Eosinophils as Biomarkers to Drive Treatment Choices in Asthma and COPD
Current Drug Targets YKL-40 as a Potential Biomarker and a Possible Target in Therapeutic Strategies of Alzheimer’s Disease
Current Neuropharmacology Editorial (Hot Topic:Modulation of Cholinergic System Activity in Neuronal and Non-Neuronal Tissues: Therapeutic Implications)
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry SARS-CoV-2 & Covid-19: Key-Roles of the ‘Renin-Angiotensin’ System / Vitamin D Impacting Drug and Vaccine Developments
Infectious Disorders - Drug Targets High Cytotoxicity and Apoptotic Effects of Natural Bioactive Benzofuran Derivative on the MCF-7 Breast Cancer Cell Line
Combinatorial Chemistry & High Throughput Screening The Therapeutic Potential of Adenosine Triphosphate as an Immune Modulator in the Treatment of HIV/AIDS: A Combination Approach with HAART
Current HIV Research Novel Mechanistic Targets for the Treatment of Sub-Acute and Chronic Bronchitis
Current Pharmaceutical Design Grinding Temperature with Nanoparticle Jet Minimum Quantity Lubrication
Recent Patents on Mechanical Engineering The Metabolic Fate of Apple Polyphenols in Humans
Current Nutrition & Food Science Mini-Review: Bmx Kinase Inhibitors for Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Neuromodulatory and Anti-Inflammatory Ingredient for Sensitive Skin: In Vitro Assessment
Inflammation & Allergy - Drug Targets (Discontinued) Design and Development of Preservative Free Herbal Dosage Forms
The Natural Products Journal Genetic Predictors of Drug Hypersensitivity
Current Pharmaceutical Design Review: The JAK/STAT Protein Activation – Role in Cancer Development and Targeted Therapy
Current Signal Transduction Therapy Low Rank Representation and Its Application in Bioinformatics
Current Bioinformatics Astragalin Attenuates UVB Radiation-induced Actinic Keratosis Formation
Anti-Cancer Agents in Medicinal Chemistry PIP3 Regulation as Promising Targeted Therapy of Mast-Cell-Mediated Diseases
Current Pharmaceutical Design